LAB: Standard BioTools Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Standard BioTools closed sale of its Microfluidics business to ARCHIMED, which will operate as Biomark Scientific; deal terms not…
What this filing says
Standard BioTools said it has closed the sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The unit will now operate as a standalone company under the name Biomark Scientific, which serves research institutions, public health laboratories and biobanks. For a shareholder, the filing reports completion of the disposition rather than any financial terms, so the price and proceeds are not stated in this excerpt.
Key figures
- Closing date
- November 3, 2026
- Business founded
- 1999
- Brand renamed
- 2022
Positive for shareholders
- The sale of the Microfluidics business has now closed, so the transaction is no longer pending.
Written by Quantisnow AI from this filing. Not financial advice.
Form 8-K cover page
Key terms
- Regulation FD Disclosure:
- An SEC rule requiring public companies to share material information broadly with all investors at the same time.
- Microfluidics:
- Technology that handles very small volumes of liquid, used here for running genomic tests on chips.
- qPCR:
- A lab method that copies and measures DNA in real time, used to detect genetic material.
FAQ
What did Standard BioTools announce about its Microfluidics business?
Standard BioTools announced with ARCHIMED that the sale of its Microfluidics business to ARCHIMED has closed. The business will continue as Biomark Scientific.
Historical context for LAB
Across the 16 sessions after earlier LAB headlines, the stock closed higher 7 times and lower 9 times, with a median move of 2.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LAB | SPY |
|---|---|---|---|
| Nov 3, 2026 | ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific | +0.1% | +0.3% |
| Oct 6, 2026 | Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED | -5.4% | +0.5% |
| Oct 1, 2026 | Standard BioTools Provides Update on Sale of Mass Cytometry Business | -1.7% | +0.2% |
| Aug 6, 2026 | Standard BioTools Reports Second Quarter 2026 Financial Results | +2.0% | -0.2% |
| Jul 28, 2026 | Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences | +2.6% | +0.2% |
| Jul 22, 2026 | Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 | -7.4% | -0.1% |
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Listed since
- 2011
Follow LAB and get a push notification the moment its next story breaks.